Apr 5th, 2019
The U.S. Farm Bill that recently passed into law is a game-changer for the CBD space. While it is unknown when nationwide cannabis legalization may occur, incredible opportunities exist right now for CBD-focused companies that can deliver products to the marketplace.
- Demand is growing for organic CBD products in markets where such products are legal.
- Youngevity has made a series of strategic acquisitions to help establish the company’s position
- Companies ready to deliver CBD products to market at scale are in ideal position to capitalize on growing demand.
Passage of the latest U.S. Farm Bill marked a watershed moment for CBD producers in the United States. Not only does the new body of law allow these producers to commercialize existing CBD products, the door is now open for a new generation of research into what CBD can do for consumers. Youngevity International Inc. (NASDAQ: YGYI) (YGYI Profile) is a leading producer of consumer-focused CBD products that is expanding its reach into other areas of the CBD supply chain. It joins companies such as CV Sciences Inc. (OTCQB: CVSI), Isodiol International Inc. (CSE: ISOL) (OTCQB: ISOLF), GW Pharmaceuticals plc (NASDAQ: GWPH) (OTC: GWPRF), and Curaleaf Holdings Inc. (OTCQX: CURLF) (CSE: CURA), which are all working to commercialize CBD products in both the consumer and pharmaceutical sectors.